

Ordering Information

Usable Length (80cm)	Usable Length (125cm)	Stent Length (mm)	Stent Diameter (mm)	Sheath
ZX05020080A	ZX05020125A	20	5	6F
ZX05030080A	ZX05030125A	30		
ZX05040080A	ZX05040125A	40		
ZX05060080A	ZX05060125A	60		
ZX05080080A	ZX05080125A	80		
ZX05100080A	ZX05100125A	100		
ZX05120080A	ZX05120125A	120		
ZX05150080A	ZX05150125A	150		
ZX06020080A	ZX06020125A	20	6	6F
ZX06030080A	ZX06030125A	30		
ZX06040080A	ZX06040125A	40		
ZX06060080A	ZX06060125A	60		
ZX06080080A	ZX06080125A	80		
ZX06100080A	ZX06100125A	100		
ZX06120080A	ZX06120125A	120		
ZX06150080A	ZX06150125A	150		
ZX07020080A	ZX07020125A	20	7	6F
ZX07030080A	ZX07030125A	30		
ZX07040080A	ZX07040125A	40		
ZX07060080A	ZX07060125A	60		
ZX07080080A	ZX07080125A	80		
ZX07100080A	ZX07100125A	100		
ZX07120080A	ZX07120125A	120		
ZX07150080A	ZX07150125A	150		

The ZENFLEX™ Pro Peripheral Drug-Eluting Stent System is indicated for improving luminal diameter in the treatment of de novo or restenotic symptomatic lesion(s) in native vascular disease of the above-the-knee femoropopliteal arteries with reference vessel diameter from 4.0 mm to 6.5 mm.



Zhejiang Zylox Medical Device Co., Ltd


Address: Floor 1&2, Building 1, No. 18 Keji Avenue, Yuhang Street, Yuhang District, Hangzhou, Zhejiang, P.R. China, 311121
TEL: (+86) 571 8861 0082 FAX: (+86) 571 8861 0608 info@zyloxmedical.com

www.zyloxtb.com

©2022 Zhejiang Zylox Medical Device Co., Ltd. All rights reserved.



ZENFLEX™ Pro
Peripheral Drug Eluting Stent System



ZENFLEX™ Pro Peripheral Drug Eluting Stent System


Stent Platform: ZENFLEX™ Peripheral Stent System

Superior Stent Design

- Open Helical Structure
- Segmented MicroMesh Design
- Offset Peak-Valley Design

Result in

- Excellent stent flexibility
- Optimal vessel conformity and coverage
- High radial strength and good fracture resistance
- Maintain a smooth vessel lumen over the long term




Unique drug coating technology of the ZENFLEX™ Pro DES

- The ZENFLEX™ Pro DES carries 3µg/mm² of Paclitaxel. The drug coating free from any polymers, adhesives, or excipients minimizes the potential risks of acute and chronic inflammation after stent implantation.
- The proprietary coating posttreatment technology can obtain a highly crystalline Paclitaxel coating layer by recrystallization, which effectively reduces the drug dissolution rate and improves the sustained release of Paclitaxel.




The dense and uniform drug coating layer of ZENFLEX™ Pro DES

- The drug coating technology ensures the effective Paclitaxel tissue concentration within 90 days. While effectively inhibiting restenosis, it also shortens the unnecessary Paclitaxel exposure time. The stent converts into a bare stent with complete drug delivery after 180 days.



Paclitaxel Particle Distribution Comparison

The ZENFLEX™ Pro's coating technology controls downstream particulate sizes and minimizes the possibility of distal embolism.



Animal Test Results

The Paclitaxel coating prevents intimal thickening within the stent and further reduces the incidence of restenosis.

